Nastya Kassir – Certara

Informing Pediatric Drug Development: A Selection from Certara’s Best of Blogs

A selection of short essays by Certara’s pediatric drug development experts. Learn about our technologies and strategies for pediatric drug development to inform dose selection, including PK/PD simulations using sparse data analysis and our Simcyp Pediatric Simulator. Certara’s regulatory writing consultancy, Synchrogenix, also offer regulatory strategy for pediatrics.

0 comments. Click here to read/write comments.

Topics:

Certara’s Best of Blogs 2015

A selection of short essays from our blog, written to empower our customers with biosimulation and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing.

0 comments. Click here to read/write comments.

Topics:

Population Pharmacodynamic/Pharmacokinetic Modeling of Eculizumab and Free Complement Component Protein C5 in Pediatric and Adult Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

0 comments. Click here to read/write comments.

Topics:

Modeling and Simulation of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) Patients: Learning from One Indication to the Next

0 comments. Click here to read/write comments.

Topics:

Equivalence of locally acting drugs based on pharmacodynamic data: a 1-step Dose-Scale method and use of trial simulations to assess sources of variability and power definitive studies

0 comments. Click here to read/write comments.

Topics:

A Modeling and Simulations Framework to Optimize Pediatric Studies and Facilitate Decision-Making

0 comments. Click here to read/write comments.

Topics:

Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Pediatric Studies

0 comments. Click here to read/write comments.

Topics:

Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma

The purpose of this study was to characterize the pharmacokinetics of oral trametinib, a first in class MEK inhibitor, identify covariates, and describe the relationship between exposure and clinical effects in patients with BRAF V600 metastatic melanoma. Trametinib concentrations obtained in three clinical studies were included in the population pharmacokinetic analysis. Trametinib 2 mg once daily was […]

0 comments. Click here to read/write comments.

Topics:

The Anatomy of a Great Biosimulation Project

Posted by Nastya Kassir

on Sep 1, 2015 1:46:52 PM

In therapeutic areas with tough competition, it is challenging to establish a complete, confident understanding of a drug’s safety and efficacy profile. Any misunderstanding of a drug’s characteristics can derail the entire development program. Biosimulation, also known as model-based drug development, uses a number of techniques, such as population PK modeling, model-based meta-analysis, and PBPK […]

0 comments. Click here to read/write comments.

Topics: PK/PD Modeling & Simulation

Pediatric Drug Dosing: Tackling Big Problems for Little Patients

Posted by Nastya Kassir

on Apr 23, 2015 3:50:05 PM

The challenges and complexities of pediatric drug development are well recognized. Pharmacometric modeling and simulation (M&S) leverages prior knowledge to support pediatric drug dosing, trial design and regulatory writing for submissions. As the benefits of pharmacometrics for drug development and regulatory decision-making become increasingly well documented, the FDA has challenged the industry to more rigorously apply […]

0 comments. Click here to read/write comments.

Topics: PK/PD Modeling & Simulation

Conversion from Twice- to Once-daily Tacrolimus in Pediatric Kidney Recipients: A Pharmacokinetic and Bioequivalence Study

The objectives of this study were to investigate pharmacokinetic and pharmacogenetic parameters during the conversion on a 1:1 (mg:mg) basis from a twice-daily (Prograf) to once-daily (Advagraf) tacrolimus formulation in pediatric kidney transplant recipients. Twenty-four-hour pharmacokinetic profiles were analyzed before and after conversion in 19 stable renal transplant recipients (age 7–19 years). Tacrolimus pharmacokinetic parameters [area […]

0 comments. Click here to read/write comments.

Topics:

Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Pediatric Liver Transplant Recipients

Objectives of this study were to develop a population pharmacokinetic (PopPK) model for tacrolimus in pediatric liver transplant patients and determine optimal sampling strategies (OSS) to accurately estimate tacrolimus exposure.

0 comments. Click here to read/write comments.

Topics:

Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox

Although smallpox has been eradicated, the United States government considers it a “material threat” and has funded the discovery and development of potential therapeutic compounds. As reported here, the human efficacious dose for one of these compounds, ST-246, was determined using efficacy studies in nonhuman primates (NHPs), together with pharmacokinetic and pharmacodynamic analysis that predicted […]

0 comments. Click here to read/write comments.

Topics:

Safety and Population Pharmacokinetic Analysis of Intravenous Acetaminophen in Neonates, Infants, Children, and Adolescents with Pain or Fever

The administration of acetaminophen via the oral and rectal routes may be contraindicated in specific clinical settings. Intravenous administration provides an alternative route for fever reduction and analgesia. This phase 1 study of intravenous acetaminophen (Ofirmev, Cadence Pharmaceuticals, Inc., San Diego, CA) in inpatient pediatric patients with pain or fever requiring intravenous therapy was designed […]

0 comments. Click here to read/write comments.

Topics: